PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1067.86%
EBIT growth above 1.5x RVPH's 5.85%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
39.05%
Operating income growth above 1.5x RVPH's 7.11%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
24.67%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
25.26%
EPS growth above 1.5x RVPH's 7.69%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
25.26%
Diluted EPS growth above 1.5x RVPH's 7.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.67%
Negative OCF growth while RVPH is at 38.83%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-25.67%
Negative FCF growth while RVPH is at 38.83%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.29%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-10.29%
Negative 5Y OCF/share CAGR while RVPH is at 21.52%. Joel Greenblatt would question the firm’s operational model or cost structure.
-46.03%
Negative 3Y OCF/share CAGR while RVPH stands at 53.59%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
68.39%
Positive 10Y CAGR while RVPH is negative. John Neff might see a substantial advantage in bottom-line trajectory.
68.39%
5Y net income/share CAGR 1.25-1.5x RVPH's 60.51%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
65.23%
3Y net income/share CAGR 1.25-1.5x RVPH's 58.01%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
-358.21%
Negative equity/share CAGR over 10 years while RVPH stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-358.21%
Negative 5Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-14.02%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.24%
We have a declining book value while RVPH shows 89.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
8.21%
We have some new debt while RVPH reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-39.30%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.